Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
Titel:
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
Auteur:
Hillmen, Peter Pitchford, Alexandra Bloor, Adrian Broom, Angus Young, Moya Kennedy, Ben Walewska, Renata Furtado, Michelle Preston, Gavin Neilson, Jeffrey R Pemberton, Nicholas Sidra, Gamal Morley, Nicholas Cwynarski, Kate Schuh, Anna Forconi, Francesco Elmusharaf, Nagah Paneesha, Shankara Fox, Christopher P Howard, Dena R Hockaday, Anna Brown, Julia M Cairns, David A Jackson, Sharon Greatorex, Natasha Webster, Nichola Shingles, Jane Dalal, Surita Patten, Piers E M Allsup, David Rawstron, Andrew Munir, Talha
Verschenen in:
Lancet oncology
Paginering:
Jaargang 24 () nr. 5 pagina's 535-552
Jaar:
2023
Inhoud:
Uitgever:
The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license